'Responsibly' priced Invokana debuts in India
This article was originally published in Scrip
Janssen has launched its selective sodium glucose co-transporter 2 (SGLT2) inhibitor Invokana (canagliflozin) for type 2 diabetes in India – sticking with its "commitment" of offering India-specific pricing for its products as far as possible.
You may also be interested in...
Significant leadership change is underway at J&J India, with Janssen India chief Sanjiv Navangul on his way out. He will be succeeded by senior J&J hand, Sarthak Ranade, who will need to handle some delicate issues pertaining to Sirturo while also keeping the flow of innovative products from the parent company to India going.
After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.